| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
64,920,000 |
| Market
Cap: |
1.01(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.43 - $23.54 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 31.4 |
| Insider 6 Months : 31.4 |
| Insider 3/6 Months : 63.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
15,238,095 |
15,238,095 |
16,248,095 |
16,248,095 |
| Total Buy Value |
$319,999,995 |
$319,999,995 |
$339,452,595 |
$339,452,595 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
2 |
2 |
| Total Shares Sold |
110,657 |
141,439 |
237,875 |
329,459 |
| Total Sell Value |
$2,164,815 |
$2,731,452 |
$4,652,676 |
$7,003,905 |
| Total People Sold |
2 |
4 |
4 |
6 |
| Total Sell Transactions |
6 |
10 |
16 |
33 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rosen Terry J |
Chief Executive Officer |
• • – |
2023-12-19 |
4 |
D |
$18.09 |
$253,260 |
D/D |
(14,000) |
3,866,526 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-12-19 |
4 |
D |
$18.09 |
$207,890 |
D/D |
(11,492) |
280,399 |
|
- |
|
| Jaen Juan C. |
President |
• • – |
2023-12-18 |
4 |
D |
$17.74 |
$108,711 |
D/D |
(6,128) |
307,734 |
|
- |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2023-12-18 |
4 |
D |
$17.74 |
$11,478 |
D/D |
(647) |
10,949 |
|
- |
|
| Nuyten Dimitry Sa |
Chief Medical Officer |
• – – |
2023-12-18 |
4 |
D |
$17.74 |
$26,734 |
D/D |
(1,507) |
72,735 |
|
- |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2023-12-18 |
4 |
D |
$17.74 |
$70,800 |
D/D |
(3,991) |
91,955 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2023-12-18 |
4 |
D |
$17.74 |
$48,767 |
D/D |
(2,749) |
56,643 |
|
- |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2023-12-18 |
4 |
D |
$17.74 |
$243,127 |
D/D |
(13,705) |
3,880,526 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-12-18 |
4 |
D |
$17.74 |
$199,575 |
D/D |
(11,250) |
291,891 |
|
- |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2023-12-01 |
4 |
AS |
$14.95 |
$4,216 |
D/D |
(282) |
11,596 |
|
3% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-09-22 |
4 |
AS |
$19.99 |
$427,166 |
D/D |
(21,369) |
302,691 |
|
-20% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-09-18 |
4 |
D |
$20.40 |
$255,122 |
D/D |
(12,506) |
324,060 |
|
- |
|
| Nuyten Dimitry Sa |
Chief Medical Officer |
• – – |
2023-09-18 |
4 |
D |
$20.40 |
$75,643 |
D/D |
(3,708) |
73,591 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-07-28 |
4 |
AS |
$20.25 |
$911,250 |
D/D |
(45,000) |
336,566 |
|
-21% |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2023-07-03 |
4 |
AS |
$20.41 |
$20,777 |
D/D |
(1,018) |
11,596 |
|
-22% |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2023-06-28 |
4 |
B |
$19.26 |
$19,452,600 |
D/D |
1,010,000 |
14,823,029 |
2.45 |
-19% |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-06-22 |
4 |
AS |
$19.12 |
$237,795 |
D/D |
(12,437) |
381,566 |
|
-22% |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2023-06-16 |
4 |
D |
$19.35 |
$169,545 |
D/D |
(8,762) |
3,894,231 |
|
- |
|
| Jaen Juan C. |
President |
• • – |
2023-06-16 |
4 |
D |
$19.35 |
$93,267 |
D/D |
(4,820) |
313,862 |
|
- |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2023-06-16 |
4 |
D |
$19.35 |
$55,960 |
D/D |
(2,892) |
95,902 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2023-06-16 |
4 |
S |
$19.35 |
$243,094 |
D/D |
(12,563) |
394,003 |
|
20% |
|
| Perlman Andrew J |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
20,925 |
|
- |
|
| Machado Clarence Patrick |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
16,900 |
|
- |
|
| Ribas Antoni |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,800 |
21,950 |
|
- |
|
| Jaen Juan C. |
President |
• • – |
2023-06-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,000 |
318,682 |
|
- |
|
207 Records found
|
|
Page 2 of 9 |
|
|
0.08 (0.51%) 
